Tag: ICH E2B(R3)

Enrollment Funnel Analytics: Find the Leaks, Lift Randomizations

Posted on digi By digi

Enrollment Funnel Analytics: Find the Leaks, Lift Randomizations Enrollment Funnel Analytics: How to Find the Leaks and Lift Randomizations with a System You Can Defend Why enrollment funnels decide study success—and how analytics turns “maybe” into predictable randomizations From activity to outcomes: measuring the right moments in the funnel Every clinical program lives or dies…

Read More “Enrollment Funnel Analytics: Find the Leaks, Lift Randomizations” »

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C)

Posted on digi By digi

Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C) From Pre-IND to IND: A US-First FDA Meeting Strategy with Reviewer-Ready Packages and Avoidable Pitfalls (Type B/C) Outcome-Oriented Game Plan: What “Good” Looks Like from Pre-IND to IND (US-First with EU/UK Mapping) Decisions before documents: frame the meeting around outcomes The most successful sponsors…

Read More “Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C)” »

US Regulatory Submissions

Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C)

Posted on digi By digi

Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C) From Pre-IND to IND: A US-First FDA Meeting Strategy with Reviewer-Ready Packages and Avoidable Pitfalls (Type B/C) Outcome-Oriented Game Plan: What “Good” Looks Like from Pre-IND to IND (US-First with EU/UK Mapping) Decisions before documents: frame the meeting around outcomes The most successful sponsors…

Read More “Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C)” »

US Regulatory Submissions

Site Activation Checklist (US & UK): Docs, Timelines, Pitfalls

Posted on digi By digi

Site Activation Checklist (US & UK): Docs, Timelines, Pitfalls Site Activation (US & UK): An Inspection-Ready Checklist of Documents, Timelines, and Pitfalls Outcome-first activation: open sites fast, safely, and in a way that survives FDA/MHRA scrutiny What “activation” must prove on day one Activation is not a flip of a calendar—it’s a verifiable condition set…

Read More “Site Activation Checklist (US & UK): Docs, Timelines, Pitfalls” »

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C)

Posted on digi By digi

Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C) From Pre-IND to IND: A US-First FDA Meeting Strategy with Reviewer-Ready Packages and Avoidable Pitfalls (Type B/C) Outcome-Oriented Game Plan: What “Good” Looks Like from Pre-IND to IND (US-First with EU/UK Mapping) Decisions before documents: frame the meeting around outcomes The most successful sponsors…

Read More “Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C)” »

US Regulatory Submissions